LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Aktien・Theravance Biopharma Inc

Theravance Biopharma Inc

Geschlossen

16.27 -0.61

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

16.24

Max

16.36

Schlüsselkennzahlen
By Trading Economics
Einkommen	-66M -4.9M
Verkäufe	-28M 18M
KGV Branchendurchschnitt	7.148 49.888
EPS	0.01
Gewinnspanne	-27.872
Angestellte	90
EBITDA	-26M -6.9M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+10.5% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	11. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-49M 822M
Vorheriger Eröffnungskurs	16.88
Vorheriger Schlusskurs	16.27

Theravance Biopharma Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Juni 2026, 19:20 UTC

Wichtige Markttreiber

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

7. Juni 2026, 23:46 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tech Selloff -- Market Talk

7. Juni 2026, 23:36 UTC

Market Talk

Oil Prices Rise Amid Escalating Supply Disruption Concerns -- Market Talk

7. Juni 2026, 18:00 UTC

Ergebnisse

Inflation Readings, Oracle Earnings, the SpaceX IPO, and More to Watch This Week -- Barrons.com

6. Juni 2026, 12:40 UTC

Akquisitionen, Fusionen, Übernahmen

Correction to Texas Billionaires Article America's Resort -- WSJ

6. Juni 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

6. Juni 2026, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

6. Juni 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. Juni 2026, 00:14 UTC

Akquisitionen, Fusionen, Übernahmen

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5. Juni 2026, 21:27 UTC

Ergebnisse

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5. Juni 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. Juni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5. Juni 2026, 20:20 UTC

Akquisitionen, Fusionen, Übernahmen

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5. Juni 2026, 20:19 UTC

Akquisitionen, Fusionen, Übernahmen

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5. Juni 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5. Juni 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. Juni 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5. Juni 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5. Juni 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5. Juni 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5. Juni 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5. Juni 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5. Juni 2026, 18:33 UTC

Akquisitionen, Fusionen, Übernahmen

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5. Juni 2026, 17:50 UTC

Ergebnisse

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5. Juni 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5. Juni 2026, 16:48 UTC

Akquisitionen, Fusionen, Übernahmen

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5. Juni 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. Juni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5. Juni 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5. Juni 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Theravance Biopharma Inc Prognose

Kursziel

By TipRanks

10.5% Vorteil

12-Monats-Prognose

Durchschnitt 18 USD 10.5%

Hoch 21 USD

Tief 15 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Theravance Biopharma Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Theravance Biopharma Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.